Satellos Bioscience Inc
XTSX:MSCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Net Insight AB
STO:NETI B
|
SE |
|
Kmc Properties ASA
LSE:0N0L
|
NO |
|
Matrimony.Com Ltd
NSE:MATRIMONY
|
IN |
|
Zhaoke Ophthalmology Ltd
HKEX:6622
|
CN |
Satellos Bioscience Inc
Total Liabilities & Equity
Satellos Bioscience Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Satellos Bioscience Inc
XTSX:MSCL
|
Total Liabilities & Equity
CA$6.2m
|
CAGR 3-Years
62%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Total Liabilities & Equity
CA$84.4m
|
CAGR 3-Years
62%
|
CAGR 5-Years
149%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Total Liabilities & Equity
$751.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
36%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Total Liabilities & Equity
$633.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
27%
|
CAGR 10-Years
26%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Total Liabilities & Equity
CA$86.2m
|
CAGR 3-Years
49%
|
CAGR 5-Years
126%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Total Liabilities & Equity
$221.5m
|
CAGR 3-Years
110%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Satellos Bioscience Inc
Glance View
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario. The company went IPO on 2006-12-01. The firm is engaged in developing therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct dysregulated muscle stem-cell polarity, which balances replenishment of muscle stem cells and production of specialized tissue cells. The company uses MyoReGenXTM discovery platform to identify regulatory pathways and drug candidates to treat muscle disorders. The company also maintains two clinical stage products: iCo-008 for potential use in eotaxin-1 mediated indications and an oral Amphotericin B delivery system. iCo-008 provides treatment of the dermatological condition bullous pemphigoid (BP), atopic dermatitis, gastrointestinal conditions, and age-related macular degeneration (AMD). Oral Amphotericin B delivery system provides treatment of Visceral Leishmaniasis (VL).
See Also
What is Satellos Bioscience Inc's Total Liabilities & Equity?
Total Liabilities & Equity
6.2m
CAD
Based on the financial report for Dec 31, 2022, Satellos Bioscience Inc's Total Liabilities & Equity amounts to 6.2m CAD.
What is Satellos Bioscience Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
35%
Over the last year, the Total Liabilities & Equity growth was -51%. The average annual Total Liabilities & Equity growth rates for Satellos Bioscience Inc have been 62% over the past three years , 35% over the past five years .
